Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology as well as a burgeoning field of genetic medicine, RNA ...

WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce ...

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is ...

Wave Life Sciences specializes in oligonucleotide therapeutics, leveraging its RNA editing platform to develop treatments for a variety of genetic disorders. The company’s approach aims to provide ...

Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...

First proof-of-concept in vivo data for RNA editing using endogenous ADAR enzymes in alpha-1 antitrypsin deficiency ADAR editing resulted in therapeutically meaningful restoration of circulating ...

CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people ...

Wave Life Sciences Ltd . (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, has been making significant ...

Chemistry optimization yields a four-fold increase over PBS control in AAT protein restoration in vivo preclinically (or more than 15 micromolar) CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- ...

CRISPR/Cas9 genome editing has captured the attention of the popular media, the scientific community and the investment world: The promise of going into a cell and precisely making changes in its ...